BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rönnblom A, Holmström T, Tanghöj H, Rorsman F, Sjöberg D. Appearance of hepatobiliary diseases in a population-based cohort with inflammatory bowel diseases (Inflammatory Bowel Disease Cohort of the Uppsala Region): Appearance of hepatobiliary diseases. J Gastroenterol Hepatol 2015;30:1288-92. [DOI: 10.1111/jgh.12947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Rocha HC, Vilela EG. Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. Gastroenterol Hepatol 2021:S0210-5705(21)00153-9. [PMID: 34023469 DOI: 10.1016/j.gastrohep.2021.03.011] [Reference Citation Analysis]
2 Lunder AK, Hov JR, Borthne A, Gleditsch J, Johannesen G, Tveit K, Viktil E, Henriksen M, Hovde Ø, Huppertz-hauss G, Høie O, Høivik ML, Monstad I, Solberg IC, Jahnsen J, Karlsen TH, Moum B, Vatn M, Negård A. Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease. Gastroenterology 2016;151:660-669.e4. [DOI: 10.1053/j.gastro.2016.06.021] [Cited by in Crossref: 98] [Cited by in F6Publishing: 77] [Article Influence: 16.3] [Reference Citation Analysis]
3 Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol 2017; 23(33): 6137-6146 [PMID: 28970729 DOI: 10.3748/wjg.v23.i33.6137] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 67] [Article Influence: 16.0] [Reference Citation Analysis]
4 Bramuzzo M, Martelossi S, Torre G, Cardile S, Arrigo S, Vignola S, Ferrari F, Zuin G, Illiceto MT, Gasparetto M, Pellegrino S, Romano C, Maggiore G, Montico M, Aloi M; SIGENP IBD Group. Clinical Features and Risk Factors of Autoimmune Liver Involvement in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2016;63:259-264. [PMID: 26756875 DOI: 10.1097/mpg.0000000000001078] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Gastroenterology 2021:S0016-5085(21)03412-0. [PMID: 34425093 DOI: 10.1053/j.gastro.2021.08.032] [Reference Citation Analysis]
6 Karaivazoglou K, Konstantakis C, Tourkochristou E, Assimakopoulos SF, Triantos C. Non-alcoholic fatty liver disease in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2020;32:903-6. [PMID: 32044821 DOI: 10.1097/MEG.0000000000001679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lampinen M, Fredricsson A, Vessby J, Martinez JF, Wanders A, Rorsman F, Carlson M. Downregulated eosinophil activity in ulcerative colitis with concomitant primary sclerosing cholangitis. J Leukoc Biol 2018;104:173-83. [DOI: 10.1002/jlb.3ma0517-175r] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
8 Wu D, Chen D, Shi W, Liu W, Zhou W, Qian J. Whole Exome Sequencing Identifies Two Novel Mutations in a Patient with UC Associated with PSC and SSA. Can J Gastroenterol Hepatol 2021;2021:9936932. [PMID: 34545326 DOI: 10.1155/2021/9936932] [Reference Citation Analysis]
9 Moran C, Sheehan D, Shanahan F. The Changing Phenotype of Inflammatory Bowel Disease. Gastroenterol Res Pract. 2016;2016:1619053. [PMID: 28050166 DOI: 10.1155/2016/1619053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Sange AH, Srinivas N, Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Syed Gaggatur N, Sange I. Extra-Intestinal Manifestations of Inflammatory Bowel Disease. Cureus 2021;13:e17187. [PMID: 34548984 DOI: 10.7759/cureus.17187] [Reference Citation Analysis]